PureGen: Radiographic Analysis of Fusion for ACDF

NCT01291134 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-03-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).

Conditions

  • Cervical Degenerative Disc Disease

Interventions

BIOLOGICAL

PureGen Osteoprogenitor Cell Allograft

PureGen Osteoprogenitor Cell Allograft.

Sponsors & Collaborators

  • Alphatec Spine, Inc.

    lead INDUSTRY

Principal Investigators

  • Bita P. Ghadimi · Alphatec Spine, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-02-29
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01291134 on ClinicalTrials.gov